Mallinckrodt Provides Update on Dutch High-Flux Reactor

November 30, 2012

Mallinckrodt, the Pharmaceutical business of Covidien, has provided an update regarding the delayed return to operation for the Dutch High-Flux Reactor (HFR).  Mallinckrodt expects to meet their customers’ needs in coming weeks, even if the HFR shutdown extends beyond mid-December.

For more information, please find the letter below.

Mallinckrodt Update on HFR